2,708
Participants
Start Date
August 1, 2025
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2029
Yangxinshi tablet
"Basic treatment: All patients received a conventional treatment regimen, including outcome-improving drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEIs)) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Yangxinshi tablet, 3 tablets/3 times a day, taken orally"
Blank control
"Basic treatment: All patients received a conventional treatment regimen, including prognosis-improving drugs (aspirin, β-blockers, statins, and ACEIs) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Blank control"
General Hospital of Northern Theater Command, Shenyang
The First Hospital of China Medical University, Shenyang
The First Affiliated Hospital of Dalian Medical University, Dalian
The Second Norman Bethune Hospital of Jilin University, Changchun
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
The First Affiliated Hospital of Ustc, Hefei
Qilu Hospital of Shandong University, Jinan
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Army Special Medical Center, Chongqing
Hebei Provincial People's Hospital, Shijiazhuang
SPH Qingdao Growful Pharmacetical Co.,Ltd
INDUSTRY